Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone

This article was originally published in Scrip

Executive Summary

Pfizer Inc. was set to reclaim the title of world's top drug maker, dramatically lower its tax rate and access billions in cash held offshore. Only now it's not doing any of that, because the US government got in the way of its plans to merge with Allergan PLC. Instead, investors are wondering what the change in plans mean for Pfizer's future as it moves forward independently.


Related Content

Pfizer, Poised For A Tax Reform Windfall, Talks About Ways To Reinvest
Pfizer Hits Pause On M&A To See How US Tax Reform Plays
Scrip's Pharma Influencers Of 2016
US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions
2016 Pharma Dealmaking: Waiting On The High-Value Deals
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts